JP2009518312A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009518312A5 JP2009518312A5 JP2008543545A JP2008543545A JP2009518312A5 JP 2009518312 A5 JP2009518312 A5 JP 2009518312A5 JP 2008543545 A JP2008543545 A JP 2008543545A JP 2008543545 A JP2008543545 A JP 2008543545A JP 2009518312 A5 JP2009518312 A5 JP 2009518312A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- plant exudate
- plant
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000000416 exudates and transudate Anatomy 0.000 claims 17
- 239000008194 pharmaceutical composition Substances 0.000 claims 17
- 102000004169 proteins and genes Human genes 0.000 claims 8
- 108090000623 proteins and genes Proteins 0.000 claims 8
- 241000124008 Mammalia Species 0.000 claims 4
- 244000005700 microbiome Species 0.000 claims 4
- 210000000987 immune system Anatomy 0.000 claims 3
- 230000036542 oxidative stress Effects 0.000 claims 3
- 241000282472 Canis lupus familiaris Species 0.000 claims 2
- 241000283086 Equidae Species 0.000 claims 2
- 241000282326 Felis catus Species 0.000 claims 2
- 241000282412 Homo Species 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 230000002503 metabolic effect Effects 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 239000003223 protective agent Substances 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000003818 metabolic dysfunction Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 238000010992 reflux Methods 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US74177405P | 2005-12-02 | 2005-12-02 | |
| PCT/US2006/046320 WO2007065024A2 (en) | 2005-12-02 | 2006-12-04 | Composition and use of phyto-percolate for treatment of disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009518312A JP2009518312A (ja) | 2009-05-07 |
| JP2009518312A5 true JP2009518312A5 (enExample) | 2011-03-03 |
Family
ID=38092904
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008543545A Pending JP2009518312A (ja) | 2005-12-02 | 2006-12-04 | 疾患を治療するための植物浸出物の組成物および使用 |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1954800A4 (enExample) |
| JP (1) | JP2009518312A (enExample) |
| AU (1) | AU2006320264A1 (enExample) |
| CA (1) | CA2631773C (enExample) |
| WO (1) | WO2007065024A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110117122A1 (en) * | 2009-11-16 | 2011-05-19 | Tiffany Thomas | COMPOSITION AND METHOD FOR AFFECTING CYTOKINES AND NF-kB |
| US7807622B2 (en) | 2004-04-23 | 2010-10-05 | Health Enhancement Products, Inc. | Composition and use of phyto-percolate for treatment of disease |
| US10166270B2 (en) | 2004-04-23 | 2019-01-01 | Zivo Bioscience, Inc. | Composition and method for affecting cytokines and NF-κB |
| CA2625818A1 (en) | 2005-04-20 | 2006-10-26 | Health Enhancement Products, Inc. | Composition and use of phyto-percolate for treatment of disease |
| CA2827401A1 (en) | 2010-02-22 | 2011-08-25 | Health Enhancement Products, Inc. | Agents and mechanisms for treating hypercholesterolemia |
| US20160051526A1 (en) * | 2013-04-09 | 2016-02-25 | Cresset Biomolecular Discovery Ltd | The Local Treatment of Inflammatory Ophthalmic Disorders |
| WO2014201372A1 (en) | 2013-06-13 | 2014-12-18 | Health Enhancement Products, Inc. | Compounds and methods for affecting cytokines |
| ES2972377T3 (es) | 2015-02-16 | 2024-06-12 | Zivo Bioscience Inc | Composiciones antinflamatorias e inmunomoduladoras que comprenden Klebsormidium y usos de las mismas |
| US11806375B2 (en) | 2016-02-16 | 2023-11-07 | Zivo Bioscience, Inc. | Nutritional support for animals via administration of an algal derived supplement |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1307213B1 (en) * | 2000-08-10 | 2004-04-28 | Ocean Nutrition Canada Ltd. | Chlorella preparations exhibiting immunomodulating properties |
| WO2005112987A2 (en) * | 2004-04-23 | 2005-12-01 | Health Enhancement Products, Inc. | Method of preparation and use of fibrinolytic enzymes in the treatment of disease |
-
2006
- 2006-12-04 EP EP06838974A patent/EP1954800A4/en not_active Withdrawn
- 2006-12-04 JP JP2008543545A patent/JP2009518312A/ja active Pending
- 2006-12-04 CA CA2631773A patent/CA2631773C/en active Active
- 2006-12-04 WO PCT/US2006/046320 patent/WO2007065024A2/en not_active Ceased
- 2006-12-04 AU AU2006320264A patent/AU2006320264A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| González-Chávez et al. | Lactoferrin: structure, function and applications | |
| Joosten et al. | Novel insights into the biology of interleukin-32 | |
| Tanno et al. | Invariant NKT cells promote skin wound healing by preventing a prolonged neutrophilic inflammatory response | |
| Raghavan et al. | Absence of CD4+ CD25+ regulatory T cells is associated with a loss of regulation leading to increased pathology in Helicobacter pylori-infected mice | |
| Wang et al. | Therapeutic potential of recombinant cystatin from Schistosoma japonicum in TNBS-induced experimental colitis of mice | |
| Steidler et al. | Therapeutic drug delivery by genetically modified Lactococcus lactis | |
| Hultgren et al. | TNF/lymphotoxin-α double-mutant mice resist septic arthritis but display increased mortality in response to Staphylococcus aureus | |
| Schwartz et al. | Interleukin 33: An innate alarm for adaptive responses beyond Th2 immunity–emerging roles in obesity, intestinal inflammation, and cancer | |
| Kelly et al. | Staphylococcus aureus-induced immunosuppression mediated by IL-10 and IL-27 facilitates nasal colonisation | |
| George et al. | Host anti-microbial response to Helicobacter pylori infection | |
| US9974815B2 (en) | Compositions comprising bacterial strains | |
| WO2008076915A3 (en) | Treatment of pigs with pcv2 antigen | |
| Takakura et al. | Influences of orally administered lactoferrin on IFN-γ and IL-10 production by intestinal intraepithelial lymphocytes and mesenteric lymph-node cells | |
| JP2012515213A5 (enExample) | ||
| Römer et al. | Endotoxins potentiate COX-2 and RANKL expression in compressed PDL cells | |
| GB2453491A (en) | Immunogenic proteins of burkholderia pseudomallei and uses thereof | |
| US20210060095A1 (en) | Combination therapy for treating or preventing cancer | |
| US20230277602A1 (en) | Combination therapy for treating or preventing cancer | |
| Puddu et al. | Role of endogenous interferon and LPS in the immunomodulatory effects of bovine lactoferrin in murine peritoneal macrophages | |
| Okita et al. | Interleukin-22-induced antimicrobial phospholipase A2 group IIA mediates protective innate immunity of nonhematopoietic cells against Listeria monocytogenes | |
| Shahid et al. | Murine and human cathelicidins contribute differently to hallmarks of mastitis induced by pathogenic Prototheca bovis algae | |
| Yang et al. | Saccharomyces boulardii administration can inhibit the formation of gastric lymphoid follicles induced by Helicobacter suis infection | |
| Kobayashi et al. | The anti-atherosclerotic dipeptide, Trp-His, reduces intestinal inflammation through the blockade of L-type Ca2+ channels | |
| Dutta et al. | The anti‐inflammatory drug Diclofenac retains anti‐listerial activity in vivo | |
| NO330984B1 (no) | Aminosyre-fenoksyestere, fremgangsmate for fremstilling av slike, mellomprodukter i synteseveien, farmasoytisk preparat omfattende slike samt anvendelse av slike for fremstilling av farmasoytisk preparat for behandling av sykdom |